POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
May 16, 2022 08:30 ET
|
POINT Biopharma
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy INDIANAPOLIS,...
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET
|
POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET
|
POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
February 08, 2022 17:27 ET
|
Telix Pharmaceuticals Limited
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based...
Telix and Monrol Expand Alliance to Include Lutetium Supply
May 10, 2021 18:57 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ISTANBUL, Turkey, May 10, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered a global clinical supply...
Telix Completes Acquisition of Atlab for Prostate Cancer Program
September 10, 2018 19:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NANTES, France, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced completion of the acquisition of Atlab Pharma SAS...